期刊文献+

丙种球蛋白联合地塞米松治疗小儿特发性血小板减少性紫癜临床观察 被引量:5

Clinical observation of gamma globulin combined with dexamethasone in children with idiopathic thrombocytopenic purpura
下载PDF
导出
摘要 目的观察丙种球蛋白联合地塞米松治疗小儿特发性血小板减少性紫癜的临床疗效。方法将特发性血小板减少性紫癜患儿30例随机分为观察组和对照组各15例。观察组予丙种球蛋白400mg.kg-1.d-1加地塞米松2mg.kg-1.d-1治疗,静脉输注3d后再改用泼尼松2mg.kg-1.d-1口服;对照组不予丙种球蛋白治疗,其余治疗同观察组。观察2组临床疗效、出血症状消失时间、血小板上升时间、血小板恢复时间及住院时间。结果观察组总有效率为93.3%高于对照组的86.7%,差异有统计学意义(P<0.05)。观察组出血症状消失时间、血小板上升时间、血小板恢复正常时间及住院时间均短于对照组,差异均有统计学意义(P<0.05)。结论丙种球蛋白联合地塞米松治疗小儿特发性血小板减少性紫癜疗效显著,值得临床推广使用。 Objective To observe the clinical effect of gamma globulin combined with dexamethasone in children with idiopathic thrombocytopenic purpura.Methods 30 cases children with idiopathic thrombocytopenic purpura were randomly divided into observation group and control group,each of 15 cases.Observation group received intravenous gammaglobulin(400mg·kg^-1·d^-1) combined with dexametrasone(2mg··kg^-1·d^-1),after 3 days,given oral prednison(2mg··kg^-1·d^-1).Control group received the same treatment with observation group except gamma globulin.Observed the clinical effect,bleeding symptoms disappear time,platelet rise time,platelet recovery time and hospital stays time of the two groups.Results The total effective rate of observation group(93.3%) was higher than that of control group(86.7%),the diffenence was syatistically significant(P〈0.05).Bleeding symptoms disappear time,platelet rise time,platelet recovery time and hospital stays time of observation group were shorter than those of control group,the diffenence were syatistically significant(P〈0.05).Conclusion The efficacy of gamma globulin combined with dexamethasone in children with idiopathic thrombocytopenic purpura is definite,and worthy of clinical application.
作者 周敏
出处 《临床合理用药杂志》 2013年第4期33-34,共2页 Chinese Journal of Clinical Rational Drug Use
关键词 紫癜 血小板减少性 丙种球蛋白 地塞米松 Purpura idiopathic thrombocytopenic Gamma globulin Dexametrasone
  • 相关文献

参考文献4

二级参考文献59

  • 1庞丽萍,杨保青,孟庆祥,柳金,张红宇,王钧,虞积仁,郭乃榄,魏颖慧,彭艳红,彭小艳.特发性血小板减少性紫癜的病因及疗效探讨[J].临床血液学杂志,2005,18(1):11-13. 被引量:16
  • 2叶任高,陆再英.内科学.人民卫生出版社,2007:813. 被引量:12
  • 3Levesque MV. Translational Mini - Review Series on B Cell - Directed Therapies:Recent advances in B cellidirected biological therapies for autoimmune disorders. Clin Exp Immunol, 2009,157 ( 2 ) 198 - 208. 被引量:1
  • 4Yu HM, Liu YF, Hou M. BAFF - an essential survival factor for B cells:links to genesis of ITP and may be of therapeutic target. Med Hypotheses,2008,70( 1 ) :40 -42. 被引量:1
  • 5Baker KP. Blys - an essential survival factor for B : basis biology,links to pathology and theraprutic target. Autommune Rev,2004,3:368 -375. 被引量:1
  • 6Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curt Opion Immunol,2005 ,17 :282 - 289. 被引量:1
  • 7Ding C. Belimumab,and anti - BlyS human monoclonal antibody for potential treatment of inflammatory autoimmune. Expert Opinl Ther,2008, 8(11) :1805 -1814. 被引量:1
  • 8Emmerich F, Bal G, Barakat A, et al. High - level serum B - cell activating factor and promoter polymorphisms in patients with idiopathic throbocytopenic purpura. Br J Haematol,2007,136 ( 2 ) : 309 - 334. 被引量:1
  • 9Zhou Z, Chen Z, Li H, et al. BAFF and BAFF - R of peripheral blood and spleen mononuclear cells in idiopathic throbocytopenic purpura. Autoimmunity, 2009,42 ( 2 ) : 112 - 119. 被引量:1
  • 10Wang T,Zhao H,Ren H,et al.Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura.Haematologica,2005,90:914-923. 被引量:1

共引文献35

同被引文献24

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部